Detection and Induction of CTLs Specific for SYT-SSX-Derived Peptides in HLA-A24+ Patients with Synovial Sarcoma1

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Immunology

• Publication date

  2002-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.4049/jimmunol.169.3.1611PMID 12133991
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection of SYT-SSX Fusion Gene in Peripheral Blood From a Patient With Synovial Sarcoma

  2001cited by this paper
• Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, a cancer‐associated retinopathy antigen, possibly related with a better prognosis in a paraneoplastic syndrome

  2001cited by this paper
• Soft tissue sarcoma as a model disease to examine cancer immunotherapy.

  2001cited by this paper
• Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations.

  2001cited by this paper
• SYT-SSX fusion proteins in synovial sarcomas: detection and characterization with new antibodies.

  2000cited by this paper
• A reverse transcriptase‐polymerase chain reaction assay in the diagnosis of soft tissue sarcomas

  2000cited by this paper
• Targeting Tumor Specific Translocations in Sarcomas in Pediatric Patients for Immunotherapy

  2000cited by this paper
• Identification of a Gene Coding for a New Squamous Cell Carcinoma Antigen Recognized by the CTL1

  2000cited by this paper
• Induction of Cytotoxic T Lymphocytes from Peripheral Blood of Human Histocompatibility Antigen (HLA)‐A31+ Gastric Cancer Patients by in vitro Stimulation with Antigenic Peptide of Signet Ring Cell Carcinoma

  2000cited by this paper
• A new era for cancer immunotherapy based on the genes that encode cancer antigens.

  1999cited by this paper
• Immunotherapeutic approaches to sarcoma.

  1999cited by this paper
• A novel fusion gene, SYT-SSX4, in synovial sarcoma.

  1999cited by this paper
• Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes.

  1999cited by this paper
• EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.

  1998cited by this paper
• SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.

  1998cited by this paper
• Diagnosis of Synovial Sarcoma with the Reverse Transcriptase‐Polymerase Chain Reaction: Analyses of 84 Soft Tissue and Bone Tumors

  1998cited by this paper
• Translocations, cancer and the puzzle of specificity

  1998cited by this paper
• Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.

  1997cited by this paper
• SSX: A multigene family with several members transcribed in normal testis and human cancer

  1997cited by this paper
• Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.

  1997cited by this paper
• Nuclear localization of SYT, SSX and the synovial sarcoma-associated SYT-SSX fusion proteins.

  1997cited by this paper
• The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40.

  1996cited by this paper
• Phenotypic Analysis of Antigen-Specific T Lymphocytes

  1996cited by this paper
• Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas.

  1995cited by this paper
• Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel‐associated box in human synovial sarcoma.

  1995influential reference
• Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules.

  1995cited by this paper
• Definition of specific peptide motifs for four major HLA-A alleles.

  1994cited by this paper
• Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma

  1994influential reference
• Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma

  1993cited by this paper
• Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma

  1993cited by this paper
• Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours

  1992cited by this paper
• Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II.

  1992cited by this paper
• Morphological and Cytogenetic Studies of a Human Synovial Sarcoma Xenotransplanted into Nude Mice

  1990cited by this paper

• Immunogenicity of neoantigens: From CAR-T cell to various vaccines.

  2025cites this paper
• The GF-NEO discovery platform unveils a [KQE][DG] sequence motif within fusion neoantigens in pediatric cancer

  2025cites this paper
• Tumor Antigens beyond the Human Exome

  2024cites this paper
• RNA vaccines for cancer: Principles to practice.

  2024cites this paper
• State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers.

  2024cites this paper
• Desmoplastic small round cell tumor: from genomics to targets, potential paths to future therapeutics

  2024cites this paper
• Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment.

  2024cites this paper
• Current Landscape of Immunotherapy for Advanced Sarcoma

  2023cites this paper
• Neoantigens: promising targets for cancer therapy

  2023cites this paper
• The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells

  2023cites this paper
• Specific recognition of an FGFR2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma

  2023cites this paper
• Identification of neoantigens for individualized therapeutic cancer vaccines

  2022cites this paper
• Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens

  2022cites this paper
• Application of additively manufactured 3D scaffolds for bone cancer treatment: a review

  2022cites this paper
• Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor

  2022cites this paper
• Gene fusion neoantigens: Emerging targets for cancer immunotherapy.

  2021cites this paper
• Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review

  2021cites this paper
• Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?

  2020cites this paper
• Immunotherapy in soft-tissue sarcoma.

  2020cites this paper
• Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.

  2020cites this paper
• Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen-specific T cells.

  2019cites this paper
• Immunogenic neoantigens derived from gene fusions stimulate T cell responses

  2019cites this paper
• Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.

  2018cites this paper
• Immunotherapies in sarcoma: Updates and future perspectives

  2017cites this paper
• Peptide vaccination therapy: Towards the next generation

  2016cites this paper
• The future of immunotherapy for sarcoma

  2016cites this paper
• Current status of engineered T-cell therapy for synovial sarcoma.

  2016cites this paper
• Key Role of DAMP in Inflammation, Cancer, and Tissue Repair.

  2016cites this paper
• [The path to innovative drug development of cancer vaccine: from discovery of tumor antigens to clinical trials].

  2014cites this paper
• Potential for immunotherapy in soft tissue sarcoma

  2014cites this paper
• A rare synovial sarcoma of the spine in the thoracic vertebral body

  2014cites this paper
• Specific Targeting of a Naturally Presented Osteosarcoma Antigen, Papillomavirus Binding Factor Peptide, Using an Artificial Monoclonal Antibody*

  2014cites this paper
• A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma

  2013cites this paper
• SYT‐SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Musculoskeletal Oncology Group

  2012cites this paper
• Vaccination using peptides spanning the SYT–SSX tumor-specific translocation

  2012cites this paper
• Phase I clinical trial of survivin‐derived peptide vaccine therapy for patients with advanced or recurrent oral cancer

  2011cites this paper
• Sarcoma Immunotherapy

  2011cites this paper
• Exploiting antitumor immunity to overcome relapse and improve remission duration

  2011cites this paper
• COMPARISON OF SPEEDY PCR-SSP METHOD AND SEROLOGICAL TYPING OF HLA-A24 FOR JAPANESE CANCER PATIENTS

  2011cites this paper
• Current Status of Immunotherapy for Osteosarcoma and its Future Trends

  2010cites this paper
• Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas

  2009cites this paper
• HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor

  2009cites this paper
• Molecular genetics of sarcomas: Applications to diagnoses and therapy

  2009cites this paper
• Cep55/c10orf3, a Tumor Antigen Derived From a Centrosome Residing Protein in Breast Carcinoma

  2009cites this paper
• Molecular pathological approaches to human tumor immunology

  2009cites this paper
• Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer

  2009cites this paper
• SYMPOSIUM: MOLECULAR GENETICS IN SARCOMA

  2008cites this paper
• Antigenic Peptide Vaccination: Provoking Immune Response and Clinical Benefit for Cancer

  2008cites this paper
• Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma

  2008cites this paper
• Identification of an Immunogenic CTL Epitope of HIFPH3 for Immunotherapy of Renal Cell Carcinoma

  2008cites this paper
• Diagnosis and management of synovial sarcoma

  2008cites this paper
• Liddy Shriver Sarcoma Initiative Chromosomal Translocations in Sarcomas : New Perspectives

  2008cites this paper
• Clonal T‐cell response against autologous pleomorphic malignant fibrous histiocytoma antigen presented by retrieved HLA‐A*0206

  2008cites this paper
• Synovial Sarcoma: From Genetics to Genetic-based Animal Modeling

  2008cites this paper
• CANCER DRUG DISCOVERY AND DEVELOPMENT

  2007cites this paper
• Clinical relevance of molecular genetics to paediatric sarcomas

  2007cites this paper
• Identification of CLUAP1 as a human osteosarcoma tumor-associated antigen recognized by the humoral immune system.

  2007cites this paper
• Discovery of Target Molecules for Cancer Immunotherapy by Genetic and Bioinformatic Approaches

  2006cites this paper
• HLA‐restricted specific tumor cytolysis by autologous T‐lymphocytes infiltrating metastatic bone malignant fibrous histiocytoma of lymph node

  2006cites this paper
• Osteosarcoma: current status of immunotherapy and future trends (Review).

  2006cites this paper
• Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches.

  2006cites this paper
• Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma

  2005cites this paper
• Disruption of Fibroblast Growth Factor Signal Pathway Inhibits the Growth of Synovial Sarcomas: Potential Application of Signal Inhibitors to Molecular Target Therapy

  2005cites this paper
• Prospects for Targeted Therapy of Synovial Sarcoma

  2005cites this paper
• Fluorescence In Situ Hybridization for the Detection of t(X;18)(p11.2;q11.2) in a Synovial Sarcoma Tissue Microarray Using a Breakapart-Style Probe

  2005cites this paper
• Tetramer analysis of human autoreactive CD4-positive T cells.

  2005cites this paper
• Molecular target therapy for synovial sarcoma.

  2005cites this paper
• Chapter 40 – Cancer – Solid Tumors

  2005cites this paper
• Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.

  2005cites this paper
• Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas

  2005cites this paper
• Journal of Translational Medicine a Quest for Therapeutic Antigens in Bone and Soft Tissue Sarcoma

  2005cites this paper
• A Potent Immunogenic General Cancer Vaccine That Targets Survivin, an Inhibitor of Apoptosis Proteins

  2005cites this paper
• Diagnosis and Management of Synovial Sarcoma

  2005cites this paper
• Identification of Human Cytotoxic T-Lymphocyte-Defined Osteosarcoma Gene That Encodes a Transcriptional Regulator, Papillomavirus Binding Factor

  2004cites this paper
• Identification of Human Autologous Cytotoxic T-Lymphocyte-Defined Osteosarcoma Gene That Encodes a Transcriptional Regulator, Papillomavirus Binding Factor

  2004cites this paper
• [Clinical applications of antigen-specific detection of T lymphocytes].

  2004cites this paper
• Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

  2004cites this paper
• La detección antígeno-específica de linfocitos T y sus aplicaciones clínicas

  2004cites this paper
• Crisscross CTL Induction by SYT-SSX Junction Peptide and Its HLA-A*2402 Anchor Substitute1

  2004cites this paper
• NOVEL APPROACH TO IMMUNOTHERAPY FOR EPITHELIAL CANCERS, BONE AND SOFT-TISSUE SARCOMAS

  2004cites this paper
• Immunity against soft-tissue sarcomas

  2003cites this paper
• Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line

  2003cites this paper
• SSX antigens as tumor vaccine targets in human sarcoma.

  2003cites this paper
• Improved generation of HLA class I/peptide tetramers.

  2002cites this paper
• Primary Cardiac Synovial Sarcoma: A Case Report and Brief Review of the Literature

  1996cites this paper
• Molecules and Cells

  year unknowncites this paper
• Journal of Translational Medicine Comparative Study on the Immunogenicity between an Hla-a24-restricted Cytotoxic T-cell Epitope Derived from Survivin and That from Its Splice Variant Survivin-2b in Oral Cancer Patients

  year unknowncites this paper